Sulfatinib: Additional Phase I data

Data from 18 evaluable patients with neuroendocrine tumors (NET) in a dose-escalation, Chinese Phase I trial showed that once-daily 200-350 mg sulfatinib led to a disease control rate (DCR) of 100% an...